Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TQA3605 added to nucleos(t)ide analog therapy in chronic hepatitis B patients with low-level viremia or suboptimal response
CTR20263352Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing TQA3605 + nucleos(t)ide analog with Placebo + nucleos(t)ide analog (2 arms). Primary endpoint: Proportion of participants with HBV DNA below 10 IU/mL at Week 48. Started Aug 2026; status: active.
02
Drugs
TQA3605
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20263352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263352.